en · de · es · fr · pt
cjc-1295-notes.peptides8425.com › Data › Background And Receptor Mechanism — What the Evidence Shows

Background And Receptor Mechanism — What the Evidence Shows

By Editorial Desk · published 2025-12-09 · last reviewed 2026-01-05 · Data

GHRH analogue comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-01-05. Numbers and descriptions here follow the published literature rather than marketing material.

Background and Receptor Mechanism

At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.

CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.

Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.

Structure And Receptor Pharmacology

Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.

CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.

Cjc-1295 at a glance

PropertyValueNotes
Molecular weight, DAC formAbout 3647 DaVaries with salt form
Molecular weight, non-DAC formAbout 3358 DaMOD GRF(1-29)
Solubility classWater solubleAlso dissolves in polar solvents
Reported half-life, DAC formAbout five to eight daysValues from human studies
Common synonymsCJC-1295; MOD GRF(1-29)Name depends on variant

Background and Molecular Design

CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.

Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.

Related pages on this site

CJC-1295 Structure And Mechanism

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.

The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.

Notes from published material

The glucose cycle is a system which is affected by two factors: entry of glucose into the bloodstream and also blood levels of insulin to control its transport out of the bloodstream As a system, it is sensitive to diet and exercise It is affected by the need for patient anticipation due to the complicating effects of time delays between any activity and the respective impact on the glucose Management is highly intrusive, and compliance is an issue, since it relies upon user lifestyle change and often upon regular sampling and measuring of blood glucose levels, multiple times a day in many cases It changes as people grow and develop It is highly individual As diabetes is a prime risk factor for cardiovascular disease, controlling other risk factors which may give rise to secondary conditions, as well as the diabetes itself, is one of the facets of diabetes management. Checking cholesterol, LDL, HDL and triglyceride levels may indicate hyperlipoproteinemia, which may warrant treatment with hypolipidemic drugs. Checking the blood pressure and keeping it within strict limits (using diet and antihypertensive treatment) protects against the retinal, renal and cardiovascular complications of diabetes. Regular follow-up by a podiatrist or other foot health specialists is encouraged to prevent the development of diabetic foot. Annual eye exams are suggested to monitor for progression of diabetic retinopathy.

Actin remains one of the most abundant proteins in all of Eukarya and is an enzyme (ATPase) that gradually hydrolyzes ATP. It exists in two forms within eukaryotic cells: globular or G-actin and filament/filamentous or F-actin. Globular actin is the monomeric form of the protein while the filamentous actin is a linear polymer of globular subunits. The assembly of filamentous actin arises as a result of weak, noncovalent interactions between G-actin and appears in the arrangement of a two-stranded asymmetrical helical polymer. The asymmetrical nature of F-actin allows for distinct binding specificities at each terminus. The terminus that presents an actin subunit with an exposed ATP binding site is commonly labeled the "(−) end". Whereas, the opposite end of the polymer that presents a cleft and lacks a free ATP binding site is referred to as the "(+) end". Additionally, the respective ends of the actin microfilament are often specified by their appearance under transmission electron microscopy during a technique known as "decoration", where the addition of myosin results in distinctive actin-myosin binding at each terminus. The terms "pointed end" and "barbed end" refer to the "(−) end" and "(+) end" respectively. Within the cell, the concentrations of G-actin and F-actin continuously fluctuate. The assembly and disassembly of F-actin is regularly known as "actin tread-milling". In this process, G-actin subunits primarily add to the "barbed end" of the filamentous polymer.

=== Activity profile === Flibanserin acts as a full agonist in the frontal cortex and the dorsal raphe nucleus, but only as a partial agonist in the CA3 region of the hippocampus of the 5-HT1A receptor (serotonin receptor) (Ki = 1 nM in CHO cells, but only 15–50 nM in cortex, hippocampus and dorsal raphe) and, with lower affinity, as an antagonist of the 5-HT2A receptor (Ki = 49 nM) and antagonist or very weak partial agonist of the D4 receptor (Ki = 4–24 nM, Ki = 8–650 nM). Flibanserin demonstrates selectivity for postsynaptic 5-HT1A receptors. Despite the much greater affinity of flibanserin for the 5-HT1A receptor, and for reasons that are unknown (although it might be caused by the competition with endogenous serotonin), flibanserin occupies the 5-HT1A and 5-HT2A receptors in vivo with similar percentages. Flibanserin also has low affinity for the 5-HT2B receptor (Ki = 89.3 nM) and the 5-HT2C receptor (Ki = 88.3 nM), both of which it behaves as an antagonist of. Flibanserin preferentially activates 5-HT1A receptors in the prefrontal cortex, demonstrating regional selectivity, and has been found to increase dopamine and norepinephrine levels and decrease serotonin levels in the rat prefrontal cortex, actions that were determined to be mediated by activation of the 5-HT1A receptor. As such, flibanserin has been described as a norepinephrine–dopamine disinhibitor (NDDI). The proposed mechanism of action refers to the Kinsey dual control model of sexual response.

In the 1990s, the national health ministries of the listed countries reviewed the pertinent studies for causal links among silicone-gel breast implants and systemic and diagnosed autoimmune diseases and breast cancer. A study by researchers at the U.S. National Institute of Health reported an increase in four types of cancer among women with breast implants compared to other plastic surgery patients of the same age and similar demographic traits and health habits. This increase in cancer was attenuated but did not disappear when the researchers followed the women for 5 more years, with a 43% increase in brain cancer and a 63% increase in respiratory cancer compared to other plastic surgery patients. A study by Watad et al. evaluated the medical records of more than 24,000 women with breast implants compared to more than 98,000 women with the same demographic traits who did not have breast implants. The researchers found a statistically significant 22 percent increase in several diagnosed diseases, increasing to more than 60% for Sjogren's syndrome, multiple sclerosis, and sarcoidosis After investigating this issue, in 2021 the U.S. FDA revised its "black box warnings" on breast implants to acknowledge the association between breast implants and systemic autoimmune, rheumatologic, and neurological symptoms to state: "Patients receiving breast implants have reported a variety of systemic symptoms, such as joint pain, muscle aches, confusion, chronic fatigue, autoimmune diseases, and others. Individual patient risk for developing these symptoms has not been well established.

=== Critical response === On Rotten Tomatoes, the first season has an approval rating of 89% based on 38 reviews, with an average rating of 7.61/10. The website's critical consensus reads: "A stellar series perfect for anyone looking for a little hope, Stargirl is delightful fun the whole family can enjoy". On Metacritic it has a weighted average score of 68 out of 100 based on 8 reviews, indicating "generally favorable reviews". Brian Lowry of CNN described the series as "hardly seeks to reinvent the wheel, or even expand the mold. Still, its mix of solid characters, clever writing and youthful exuberance casts a brighter light than most". Daniel Fienberg of The Hollywood Reporter gave a review, calling it "derivative, but should fill the superhero-origin-story-shaped hole in your heart" and wrote: "The result is that a show that is frequently derivative to the point of distraction might actually fill a need for viewers able to concentrate on its occasional charms until better superhero shows return". On Rotten Tomatoes, the second season holds an approval rating of 100% based on 5 reviews, with an average rating of 8.2/10.

Sources: en.wikipedia.org

Background from the literature

=== Death === Ingestion of high quantities of capsaicin can be deadly, particularly in people with heart problems. Even healthy young people can suffer adverse health effects like myocardial infarction after ingestion of capsaicin capsules.

=== Major users' response === Beginning around 2000, as the scientific evidence and public concern about trans fat increased, major American users of trans fat began to switch to safer alternatives. The process received a large boost in 2003 when the FDA announced it would require trans fat labeling on packaged food starting in 2006. Packaged food companies then faced the choice of either eliminating trans fat from their products, or having to declare the trans fat on their nutrition label. Lawsuits in the U.S. against trans fat users also encouraged its removal. Major American fast food chains including McDonald's, Burger King, KFC and Wendy's reduced and then removed partially hydrogenated oils (containing artificial trans fats) by 2009. This was a major step toward trans fat removal, as french fries were one of the largest sources of trans fat in the American diet, with a large serving of fries typically having about 6 grams of trans fat until around 2007. Two other events were important in the removal of trans fat. First, in 2013 the FDA announced it planned to completely ban artificial trans fat in the form of partially hydrogenated oil. Second, soon after this, Walmart informed its suppliers they needed to remove trans fat by 2015 if they wanted to continue to sell their products at its stores. As Walmart is the largest brick-and-mortar retailer in the U.S., mainstream food brands had little choice but to comply.

==== Immunity boosters ==== Antioxidants help support the development of a healthy immune system by preventing the oxidation of essential molecules in a growing kitten. Antioxidants in kitten diets can be derived from plant ingredients such as carrots, sweet potatoes, and spinach, as well as from dietary supplements like vitamin E and zinc proteinate.

Wang Xuefeng, who is the chief executive and the shareholder of Zhenhua Data, has publicly boasted that he supports "hybrid warfare" through manipulation of public opinion and "psychological warfare". In February 2024 The Philippines announced that it had successfully fought off a cyber attack which was traced to hackers in China. Several government websites were targeted including the National coast watch and personal website of the president of the Philippines, Bongbong Marcos. In May 2024 The UK announced that it had taken a database offline that is used by its defense ministry after coming under a cyber attack attributed to the Chinese state.

Sources: en.wikipedia.org

Frequently asked questions

What is CJC-1295?

It is a synthetic peptide modeled on growth hormone-releasing hormone. The molecule is used in research on pituitary growth hormone secretion. It differs from the natural hormone through several stabilizing substitutions.

How do the DAC and non-DAC forms differ?

The DAC form carries a maleimide group that binds albumin and extends circulation time. The non-DAC form lacks this group and clears much faster. Both share the same receptor-binding core.

What receptor does it act on?

It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Activation raises cyclic AMP and promotes growth hormone release. Normal feedback pathways remain part of the response.

Is CJC-1295 the same as modified GRF(1-29)?

The names are often used interchangeably in casual writing, but they are not strictly identical. Modified GRF(1-29) refers to the unconjugated analogue carrying only the four substitutions. The version sold as CJC-1295 with DAC includes the albumin binding linker and clears much more slowly.

Network